SFJ Pharmaceuticals Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • SFJ Pharmaceuticals's estimated annual revenue is currently $7.8M per year.(i)
  • SFJ Pharmaceuticals's estimated revenue per employee is $201,000

Employee Data

  • SFJ Pharmaceuticals has 39 Employees.(i)
  • SFJ Pharmaceuticals grew their employee count by 3% last year.

SFJ Pharmaceuticals's People

NameTitleEmail/Phone
1
CFOReveal Email/Phone
2
VP, Clinical and Asset LeadReveal Email/Phone
3
EVP and Chief Accounting OfficerReveal Email/Phone
4
Head CMCReveal Email/Phone
5
SVP, Clinical Development, Asia PacificReveal Email/Phone
6
Chief Regulatory OfficerReveal Email/Phone
7
Senior Director, Head Statistical Programming and Data StandardsReveal Email/Phone
8
Senior Director, Regulatory AffairsReveal Email/Phone
9
Chief Medical OfficerReveal Email/Phone
10
EVP and Chief Business OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$84.8M42224%N/AN/A
#2
$0.4M20%N/AN/A
#3
$32M1593%N/AN/A
#4
$35M1213%$62.5MN/A
#5
$30.2M15018%N/AN/A
#6
$135.3M6730%N/AN/A
#7
$110.3M549N/AN/AN/A
#8
$60.1M299-4%N/AN/A
#9
$554.8M17252%N/AN/A
#10
$10.5M524%N/AN/A
Add Company

What Is SFJ Pharmaceuticals?

The SFJ Pharmaceuticals Group is a Specialty Pharma Company deploying a new business model for the clinical development and registration of pharmaceutical products. Established in 2009, SFJ provides a financially advantageous and creative alternative approach to partnering. SFJ can provide the strategic financing, clinical development and regulatory resources for the clinical development and approval or your products. SFJ is staffed with a seasoned team of professionals, with extensive experience in the clinical development and regulatory approval of pharmaceutical products on a global basis. SFJ has offices in the United States, Europe, Japan, Singapore, Caymans, and Korea.

keywords:N/A

N/A

Total Funding

39

Number of Employees

$7.8M

Revenue (est)

3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

SFJ Pharmaceuticals News

2022-04-17 - Nektar, BMS quash cancer collaboration once billed as $3.6 ...

... Nektar said it will discontinue its bempeg trials with Pleasanton-based SFJ Pharmaceuticals that combined the drug with Merck & Co.

2022-04-17 - Head to Head Review: Calliditas Therapeutics AB (publ ...

PhaseBio Pharmaceuticals has a consensus price target of $12.50, ... agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452,...

2022-04-13 - Nektar stops clinical trials for key cancer drug, shares tumble

... agreement signed in 2020, while the one with Keytruda involved a partnership entered with privately owned SFJ Pharmaceuticals last year.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.6M4033%N/A
#2
$4.3M40-31%$11.7M
#3
$6.7M405%N/A
#4
$8.9M415%N/A
#5
$6.7M418%N/A